PHILADELPHIA–(BUSINESS WIRE). PCT-3012, a novel G protein-dependent D3 receptor agonist to reduce motor impairment in Parkinson’s disease through IND-enabling work.
“Nearly 60,000 new cases of Parkinson’s disease are diagnosed in the United States each year, and the current gold standard for treating motor symptoms results in dyskinesia in nearly 50% of patients treated for more than four years. Concern about developing these involuntary, erratic facial and body movements is causing some patients to delay treatment,” said Chris Garabedian, Xontogeny’s chairman and chief executive officer. “We are excited to support the PolyCore team in advancing their novel compound through preclinical studies as we believe this new therapeutic could significantly improve the lives of patients with Parkinson’s disease by reducing motor symptoms without the development of Tolerance or dyskinesia improved.”
Over 1 million Americans are living with Parkinson’s disease. The current standard of care to treat the symptoms of Parkinson’s disease is levodopa (L-dopa). Within 3 to 5 years of treatment, about 50% of patients develop tolerance to the drug, requiring higher doses to be taken more frequently; this dose increase can cause L-Dopa-induced dyskinesia, which is manifested as abnormal, involuntary body movements that impair patients’ quality of life. PolyCore is developing PCT-3012, a novel dopamine D3 receptor agonist with a significantly differentiated mechanism of action that improve motor symptoms without developing tolerance, impulse control disorders and dyskinesia.
“We are very excited to be collaborating with the team at Xontogeny as we work to advance our lead compound through IND-enabling studies. Additionally, we appreciate the continued support of Ben Franklin Technology Partners in this round,” said Kelly Beck, CEO of PolyCore Therapeutics. “As the world population continues to age, it is important that we continue to identify treatments that not only address the symptoms of Parkinson’s disease, but also do not introduce new side effects such as dyskinesia, which can incredibly impact a patient’s quality of life. The resources provided by this seed investment will allow us to rapidly advance our technology and accelerate our ability to bring our technology to the clinic.”
PCT-3012 is a novel D3 receptor agonist that induces G protein signaling without causing receptor desensitization over time. Conventional dopamine agonists such as L-dopa signal through both G-protein and β-arrestin signaling pathways, the latter presumably causing long-term receptor desensitization that ultimately leads to tolerance and hyperactivation of neurons, resulting in dyskinesia. PCT-3012 was designed not to recruit or signal the β-arrestin pathway, resulting in an enhanced compound compared to traditional dopamine agonists.
The Board of Directors will consist of Chris Garabedian, CEO of Xontogeny, Fred Callori, SVP of Corporate Development at Xontogeny, Jim Harris, Co-Founder of PolyCore, Kelly Beck, CEO of PolyCore, and Chris Cashman as an independent director.
About PolyCore Therapeutics, Inc.
PolyCore Therapeutics, Inc. is a biopharmaceutical company developing treatments for patients suffering from dyskinesia and cognitive impairment associated with neurodegenerative diseases. PolyCore is currently conducting preclinical studies for its lead compound PCT-3012, a novel small molecule for the treatment of motor symptoms and dyskinesias of Parkinson’s disease in patients with early to mid-stage Parkinson’s disease. For more information, visit www.polycoretherapeutics.com.
About Xontogeny, LLC
Based in Boston, MA, Xontogeny seeks to accelerate the development of life science technologies by providing entrepreneurs with funding opportunities, as well as the leadership, strategic guidance and operational support needed to increase the likelihood of success in early drug and technology development to increase. Through a differentiated approach, the Xontogeny team works with founding scientists and entrepreneurs to support their vision while enabling a more efficient development model that benefits company founders and early shareholders. Visit www.xontogeny.com for more information